While some BrCa patients are treated with gemcitabine, the addition of a CHK1 inhibitor may offer the possibility of achieving a better therapeutic response or an improved response using a lower dose of gemcitabine for patients who may be more susceptible to the side effects of gemcitabine. The gene discussed is CHEK1; the disease is invasive breast carcinoma.